A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Titel:
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Auteur:
Lin, Nancy U. Winer, Eric P. Wheatley, Duncan Carey, Lisa A. Houston, Stephen Mendelson, David Munster, Pamela Frakes, Laurie Kelly, Steve Garcia, Agustin A. Cleator, Susan Uttenreuther-Fischer, Martina Jones, Hilary Wind, Sven Vinisko, Richard Hickish, Tamas